ULBI Ultralife

Ultralife Corporation Reports Third Quarter Results

Ultralife Corporation Reports Third Quarter Results

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

  • Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%
  • Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024
  • Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024
  • GAAP EPS of ($0.07) compared to $0.02 for the third quarter of 2024
  • Adjusted EBITDA of $2.0 million compared to $1.9 million for the third quarter of 2024
  • Backlog of $90.1 million exiting the third quarter of 2025 compared to $84.5 million exiting the second quarter of 2025

During the third quarter of 2025, Ultralife made the decision to close its battery pack assembly facility located in Calgary, Canada. Accordingly the Company recorded a $.5 million charge to cover employee severance and termination costs, the remaining lease costs which run through July 31, 2026 and the estimated costs to close the facility and relocate the equipment and inventory to the Company’s facility in Houston, Texas. Management expects to complete the closure in the first quarter of 2026 and to realize estimated annual savings of approximately $.8 million thereafter primarily resulting from the reduction of labor and the elimination of the leased facility.

“Although revenue grew 2.5% organically and 21.5% including the Electrochem acquisition for the third quarter, supply chain issues caused manufacturing inefficiencies in our Battery & Energy Products business and orders continued to be delayed in our Communications Systems business, both of which impacted overall profitability. In response, we are intensifying our lean and process improvement initiatives, improving supply chain resiliency and rationalizing our manufacturing operations,” said Mike Manna, President and Chief Executive Officer.

“These actions are critical to ensuring we are best prepared to optimize the operating leverage of our business model as we advance several new products into qualification and production, and capitalize on an expanding pipeline of opportunities consisting primarily of large, multi-year programs,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”

Third Quarter 2025 Financial Results

Revenue was $43.4 million, an increase of $7.7 million, or 21.5%, as compared to revenue of $35.7 million for the third quarter of 2024. Battery & Energy Products sales increased 22.8% to $39.9 million compared to $32.5 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales increased 1.9% with government/defense sales increasing 19.0%, reflecting strong demand from a U.S.-based global prime, partially offset by a 5.7% decrease in commercial sales, primarily reflecting declines in oil & gas and medical sales. Communications Systems sales increased 8.2% to $3.4 million compared to $3.2 million for the same period last year.

Gross profit was $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 22.1%, compared to 24.7% last year, primarily due to manufacturing inefficiencies resulting from quality issues associated with some incoming raw materials lowering factory throughput at some of our locations and less favorable sales mix. Communications Systems gross margin was 23.3% compared to 20.0% last year, primarily due to product mix.

Operating expenses were $10.6 million, compared to $8.2 million for the third quarter of 2024, reflecting the inclusion of Electrochem and one-time non-recurring costs of $1.1 million related to the closing of our Calgary facility, costs related to our acquisition of Electrochem and transition to Ultralife systems, and litigation expenses incurred for our cyber insurance claim. Operating expenses were 24.4% of revenue compared to 22.9% of revenue for the year-earlier period. Excluding the one-time costs, operating expenses were 21.9% of revenues for the third quarter of 2025.

Operating loss was $1.0 million compared to operating income of $.5 million last year, primarily resulting from the one-time non-recurring expenses incurred and lower gross margin for our Battery & Energy Products segment in 2025.  

Other expense, reported below operating income was $.8 million, comprised of interest expense from the financing of our Electrochem acquisition on October 31, 2024 and foreign currency gains from the strengthening of the U.S. dollar, compared to $.2 million for the same period last year.   

Net (loss) income attributable to Ultralife Corporation was ($1.2) million or ($0.07) per basic and diluted share on a GAAP basis, compared to $.3 million or $0.02 per diluted share for the third quarter of 2024.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $2.0 million for the third quarter of 2025, or 4.7% of sales, compared to $1.9 million, or 5.4% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.5 million or 8.3% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit .

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: . This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at . For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.



     
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)
(Unaudited)
 
ASSETS

     
 September 30,

2025
 December 31,

2024
 
Current Assets:    
Cash$9,260 $6,854 
Trade Accounts Receivable, Net30,929 29,370 
Inventories, Net52,747 51,363 
Prepaid Expenses and Other Current Assets7,683 9,573 
Total Current Assets100,619 97,160 
     
Property, Plant and Equipment, Net40,536 40,485 
Goodwill45,336 45,006 
Other Intangible Assets, Net23,407 24,557 
Deferred Income Taxes, Net8,212 8,413 
Other Non-Current Assets4,136 4,830 


Total Assets
$222,246 $220,451 
 


LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:

Accounts Payable$14,164 $14,160 
Current Portion of Long-Term Debt3,781 2,750 
Accrued Compensation and Related Benefits2,935 2,911 
Accrued Expenses and Other Current Liabilities12,818 9,470 
Total Current Liabilities33,698 29,291 
Long-Term Debt, Net46,518 51,502 
Deferred Income Taxes1,358 1,443 
Other Non-Current Liabilities3,239 4,028 
Total Liabilities84,813 86,264 
     
Shareholders' Equity:    
Common Stock2,109 2,107 
Capital in Excess of Par Value192,622 191,828 
Accumulated Deficit(32,918) (34,442) 
Accumulated Other Comprehensive Loss(3,058) (4,006) 
Treasury Stock(21,492) (21,492) 
Total Ultralife Equity137,263 133,995 
Non-Controlling Interest170 192 
Total Shareholders’ Equity137,433 134,187 
     
Total Liabilities and Shareholders' Equity$222,246 $220,451 



 
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)

        
 Three-Month Period Ended Nine-Month Period Ended
 September 30, September 30, September 30, September 30,
 2025 2024 2025 2024
Revenues:       
Battery & Energy Products$39,946 $32,529

 $132,134 $104,201
Communications Systems3,425 3,165 10,544 16,403
Total Revenues43,371 35,694 142,678 120,604
        
Cost of Products Sold:       
Battery & Energy Products31,126 24,482 101,039 77,215
Communications Systems2,626 2,530 7,674 11,674
Total Cost of Products Sold33,752 27,012 108,713 88,889
        
Gross Profit9,619 8,682 33,965 31,715
        
Operating Expenses:       
Research and Development2,855 2,101 7,577 5,854
Selling, General and Administrative7,715 6,070 21,684 17,370
Total Operating Expenses10,570 8,171 29,261 23,224
        
Operating (Loss) Income(951) 511 4,704 8,491
        
Other Expense800 158 2,896 685
(Loss) Income Before Income Taxes(1,751) 353 1,808 7,806

        
Income Tax (Benefit) Provision(504) 74 306 1,630
        
Net (Loss) Income(1,247) 279 1,502 6,176
        
Net (Loss) Income Attributable to Non-Controlling Interest(27) 21 (22) 58
        
Net (Loss) Income Attributable to Ultralife Corporation($1,220) $258 $1,524 $6,118
        
        
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic($.07) $.02 $.09 $.37
        
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted($.07) $.02 $.09 $.37
        
Weighted Average Shares Outstanding – Basic16,646 16,625 16,638 16,530
        
Weighted Average Shares Outstanding – Diluted16,646 16,874 16,699 16,742



Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.





ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

    
 Three-Month Period Ended Nine-Month Period Ended
 September 30,

2025
 September 30,

2024
 September 30,

2025
 September 30,

2024
        
Net (Loss) Income Attributable to Ultralife Corporation($1,220) $258 $1,524 $6,118
Adjustments:       
Interest Expense, Net992 173 3,016 1,111
Income Tax (Benefit) Provision(504) 74 306 1,630
Depreciation Expense1,008 765 2,966 2,294
Amortization Expense411 229 1,226 684
Stock-Based Compensation Expense236 170 698 490
Severance and Other Costs for Plant Closure491 - 641 -
Acquisition and Other Non-Recurring Costs594 250 1,112 -
Non-Cash Purchase Accounting Adjustment40 - 120 250
Adjusted EBITDA$2,048 $1,919 $11,609 $12,577



Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

 Investor Relations Contact:

Alliance Advisors IR

Jody Burfening/Alex Villalta

(212) 838-3777



EN
18/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultralife

Ultralife Corp: 1 director

A director at Ultralife Corp bought 53,900 shares at 4.971USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Ultralife Corporation Reports Third Quarter Results

Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1...

 PRESS RELEASE

Ultralife Corporation to Report Third Quarter Results on November 18, ...

Ultralife Corporation to Report Third Quarter Results on November 18, 2025 NEWARK, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 18, 2025.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conferenc...

 PRESS RELEASE

Ultralife Corporation Files Form 12b-25 Notification of Late Filing

Ultralife Corporation Files Form 12b-25 Notification of Late Filing NEWARK, N.Y., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Form 10-Q for the third quarter ended September 30, 2025. As previously disclosed, on October 31, 2024, Ultralife completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. (“Electrochem”) from Integer Holdings Corporation (“Integer”). During the third quarter of 2025, th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch